Cargando…

Two or More Synchronous Combination of Noninvasive Tests to Increase Accuracy of Liver Fibrosis Assessement in Chronic Hepatitis C; Results From a Cohort of 446 Patients

BACKGROUND: The prediction of fibrosis is an essential part of the assessment and management of patients with chronic liver disease. Non-invasive tests (NITs) have a number of advantages over the traditional standard of fibrosis assessment by liver biopsy, including safety, cost-effectiveness, and w...

Descripción completa

Detalles Bibliográficos
Autores principales: Crisan, Dana, Radu, Corina, Lupsor, Monica, Sparchez, Zeno, Grigorescu, Mircea Dan, Grigorescu, Mircea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Kowsar 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3339417/
https://www.ncbi.nlm.nih.gov/pubmed/22550525
http://dx.doi.org/10.5812/hepatmon.853
_version_ 1782231353359597568
author Crisan, Dana
Radu, Corina
Lupsor, Monica
Sparchez, Zeno
Grigorescu, Mircea Dan
Grigorescu, Mircea
author_facet Crisan, Dana
Radu, Corina
Lupsor, Monica
Sparchez, Zeno
Grigorescu, Mircea Dan
Grigorescu, Mircea
author_sort Crisan, Dana
collection PubMed
description BACKGROUND: The prediction of fibrosis is an essential part of the assessment and management of patients with chronic liver disease. Non-invasive tests (NITs) have a number of advantages over the traditional standard of fibrosis assessment by liver biopsy, including safety, cost-effectiveness, and widespread accessibility. OBJECTIVES: The aim of this study was to determine the accuracy of certain biomarkers and transient elastography (TE) alone or in combination to predict the stage of liver fibrosis in chronic hepatitis C (CHC). Also, we examined whether the combination of certain biomarkers and TE could increase the diagnostic accuracy of liver fibrosis assessment. PATIENTS AND METHOD: A total of 446 patients who were previously diagnosed with CHC were included in the study. In the study group, 6 blood-based scores (APRI, Forns, Fib-4, Hepascore, FibroTest, and Fibrometer) were calculated, and TE was performed to validate the stage of fibrosis, compared with liver biopsy (LB) as the standard. RESULTS: Significant fibrosis (F ≥ 2) was predicted with an AUROC of 0.727, 0.680, 0.714, 0.778, 0.688, 0.797, and 0.751 for the APRI, Forns, Fib-4, FibroTest, Hepascore, and Fibrometer scores and TE (Fibroscan), respectively. Severe fibrosis (F ≥ 3) was predicted, with AUROCs ranging between 0.705 and 0.811 for Hepascore and Fibrometer, respectively. Of the biomarkers, Fibrometer had the highest AUROC value in predicting both significant and severe fibrosis. The combination of APRI or FIB-4 with Fibrometer increased the diagnostic accuracy for significant fibrosis (from 69.07 to 82.27 for APRI, P = 0.001 and from 57.74 to 81.33, P = 0.001 for Fib-4). Combining APRI or Fib-4 with TE also increased the diagnostic accuracy (from 69.07 to 80.70%, P = 0.001 for APRI and from 57.74 to 81.33%, P = 0.001 for Fib-4) for significant fibrosis. The association that included Fibrotest was also reliable for the improvement of diagnostic accuracy. These combinations were more accurate or the assessment of severe fibrosis. CONCLUSIONS: The synchronous association between a simple, inexpensive score and a complex but expensive score or TE increases the diagnostic accuracy of non-invasive methods for the assessment of liver fibrosis stage.
format Online
Article
Text
id pubmed-3339417
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Kowsar
record_format MEDLINE/PubMed
spelling pubmed-33394172012-05-01 Two or More Synchronous Combination of Noninvasive Tests to Increase Accuracy of Liver Fibrosis Assessement in Chronic Hepatitis C; Results From a Cohort of 446 Patients Crisan, Dana Radu, Corina Lupsor, Monica Sparchez, Zeno Grigorescu, Mircea Dan Grigorescu, Mircea Hepat Mon Original Article BACKGROUND: The prediction of fibrosis is an essential part of the assessment and management of patients with chronic liver disease. Non-invasive tests (NITs) have a number of advantages over the traditional standard of fibrosis assessment by liver biopsy, including safety, cost-effectiveness, and widespread accessibility. OBJECTIVES: The aim of this study was to determine the accuracy of certain biomarkers and transient elastography (TE) alone or in combination to predict the stage of liver fibrosis in chronic hepatitis C (CHC). Also, we examined whether the combination of certain biomarkers and TE could increase the diagnostic accuracy of liver fibrosis assessment. PATIENTS AND METHOD: A total of 446 patients who were previously diagnosed with CHC were included in the study. In the study group, 6 blood-based scores (APRI, Forns, Fib-4, Hepascore, FibroTest, and Fibrometer) were calculated, and TE was performed to validate the stage of fibrosis, compared with liver biopsy (LB) as the standard. RESULTS: Significant fibrosis (F ≥ 2) was predicted with an AUROC of 0.727, 0.680, 0.714, 0.778, 0.688, 0.797, and 0.751 for the APRI, Forns, Fib-4, FibroTest, Hepascore, and Fibrometer scores and TE (Fibroscan), respectively. Severe fibrosis (F ≥ 3) was predicted, with AUROCs ranging between 0.705 and 0.811 for Hepascore and Fibrometer, respectively. Of the biomarkers, Fibrometer had the highest AUROC value in predicting both significant and severe fibrosis. The combination of APRI or FIB-4 with Fibrometer increased the diagnostic accuracy for significant fibrosis (from 69.07 to 82.27 for APRI, P = 0.001 and from 57.74 to 81.33, P = 0.001 for Fib-4). Combining APRI or Fib-4 with TE also increased the diagnostic accuracy (from 69.07 to 80.70%, P = 0.001 for APRI and from 57.74 to 81.33%, P = 0.001 for Fib-4) for significant fibrosis. The association that included Fibrotest was also reliable for the improvement of diagnostic accuracy. These combinations were more accurate or the assessment of severe fibrosis. CONCLUSIONS: The synchronous association between a simple, inexpensive score and a complex but expensive score or TE increases the diagnostic accuracy of non-invasive methods for the assessment of liver fibrosis stage. Kowsar 2012-03 2012-03-28 /pmc/articles/PMC3339417/ /pubmed/22550525 http://dx.doi.org/10.5812/hepatmon.853 Text en Copyright © 2012, Kowsar Corp. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Crisan, Dana
Radu, Corina
Lupsor, Monica
Sparchez, Zeno
Grigorescu, Mircea Dan
Grigorescu, Mircea
Two or More Synchronous Combination of Noninvasive Tests to Increase Accuracy of Liver Fibrosis Assessement in Chronic Hepatitis C; Results From a Cohort of 446 Patients
title Two or More Synchronous Combination of Noninvasive Tests to Increase Accuracy of Liver Fibrosis Assessement in Chronic Hepatitis C; Results From a Cohort of 446 Patients
title_full Two or More Synchronous Combination of Noninvasive Tests to Increase Accuracy of Liver Fibrosis Assessement in Chronic Hepatitis C; Results From a Cohort of 446 Patients
title_fullStr Two or More Synchronous Combination of Noninvasive Tests to Increase Accuracy of Liver Fibrosis Assessement in Chronic Hepatitis C; Results From a Cohort of 446 Patients
title_full_unstemmed Two or More Synchronous Combination of Noninvasive Tests to Increase Accuracy of Liver Fibrosis Assessement in Chronic Hepatitis C; Results From a Cohort of 446 Patients
title_short Two or More Synchronous Combination of Noninvasive Tests to Increase Accuracy of Liver Fibrosis Assessement in Chronic Hepatitis C; Results From a Cohort of 446 Patients
title_sort two or more synchronous combination of noninvasive tests to increase accuracy of liver fibrosis assessement in chronic hepatitis c; results from a cohort of 446 patients
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3339417/
https://www.ncbi.nlm.nih.gov/pubmed/22550525
http://dx.doi.org/10.5812/hepatmon.853
work_keys_str_mv AT crisandana twoormoresynchronouscombinationofnoninvasiveteststoincreaseaccuracyofliverfibrosisassessementinchronichepatitiscresultsfromacohortof446patients
AT raducorina twoormoresynchronouscombinationofnoninvasiveteststoincreaseaccuracyofliverfibrosisassessementinchronichepatitiscresultsfromacohortof446patients
AT lupsormonica twoormoresynchronouscombinationofnoninvasiveteststoincreaseaccuracyofliverfibrosisassessementinchronichepatitiscresultsfromacohortof446patients
AT sparchezzeno twoormoresynchronouscombinationofnoninvasiveteststoincreaseaccuracyofliverfibrosisassessementinchronichepatitiscresultsfromacohortof446patients
AT grigorescumirceadan twoormoresynchronouscombinationofnoninvasiveteststoincreaseaccuracyofliverfibrosisassessementinchronichepatitiscresultsfromacohortof446patients
AT grigorescumircea twoormoresynchronouscombinationofnoninvasiveteststoincreaseaccuracyofliverfibrosisassessementinchronichepatitiscresultsfromacohortof446patients